Drug
007c MA
007c MA: highest development phase Phase 2, developed by MapLight Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- MapLight Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ML-007C-MA NCT06887192 | Phase 2 | Psychosis Associated With Alzheimer's Disease |
| ML-007C-MA NCT07459660 | Phase 2 | Psychosis Associated With Alzheimer's Disease |
Latest
No recent events.
Follow 007c MA on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.